CRISPR‐Cas9 technology: As an efficient genome modification tool in the cancer diagnosis and treatment

Abstract Cancer is the second most common cause of death globally and is a major public health concern. Managing this disease is difficult due to its multiple stages and numerous genetic and epigenetic changes. Traditional cancer diagnosis and treatment methods have limitations, making it crucial to develop new modalities to combat the increasing burden of cancer. The clustered regularly interspaced short palindromic repeats (CRISPR)‐CRISPR‐associated protein 9 (Cas9) system has transformed genetic engineering due to its simplicity, specificity, low cytotoxicity, and cost‐effectiveness. It has been proposed as an effective technology to enhance cancer diagnosis and treatment strategies. This article presents the most recent discoveries regarding the structure, mechanism, and delivery methods of the highly powerful genome editing tool, CRISPR‐Cas9. In terms of diagnosis, the article examines the role of CRISPR‐Cas9 in detecting microRNAs and DNA methylation, and discusses two popular gene detection techniques that utilize the CRISPR‐Cas system: DNA endonuclease‐targeted CRISPR trans reporter and specific high sensitivity enzymatic reporter unlocking. Regarding treatment, the article explores several genes that have been identified and modified by CRISPR‐Cas9 for effective tumorigenesis of common cancers such as breast, lung, and colorectal cancer. The present review also addresses the challenges and ethical issues associated with using CRISPR‐Cas9 as a diagnostic and therapeutic tool. Despite some limitations, CRISPR‐Cas9‐based cancer diagnosis has the potential to become the next generation of cancer diagnostic tools, and the continuous progress of CRISPR‐Cas9 can greatly aid in cancer treatment.